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Abstract 
Trials in normal older women and in patients with renal impairment suggest that 
calcium supplements increase the risk of cardiovascular disease. To further assess 
their safety, we recently conducted a meta-analysis of trials of calcium supplements, 
and found a 27-31% increase in risk of myocardial infarction, and a 12-20% increase 
in risk of stroke. These findings are robust because they are based on pre-specified 
analyses of randomized, placebo-controlled trials and show consistent risk across the 
trials. The fact that cardiovascular events were not primary endpoints of any of these 
studies will introduce noise but not bias into the data. A recent re-analysis of the 
Women’s Health Initiative suggests that co-administration of vitamin D with calcium 
does not lessen these adverse effects.   
 
The increased cardiovascular risk with calcium supplements is consistent with 
epidemiological data relating higher circulating calcium concentrations to 
cardiovascular disease in normal populations. There are several possible 
pathophysiological mechanisms for these effects, including effects on vascular 
calcification, on the function of vascular cells, and on blood coagulation. Calcium-
sensing receptors might mediate some of these effects.  
 
Because calcium supplements produce small reductions in fracture risk and a small 
increase in cardiovascular risk, there may be no net benefit from their use. Food 
sources of calcium appear to produce similar benefits on bone density although their 
effects on fracture are unclear. Since food sources have not been associated with 
adverse cardiovascular effects, they may be preferable. Available evidence suggests 
that other osteoporosis treatments are still effective without calcium co-
administration. 
Introduction 
The concept that the use of calcium supplements might impact on the incidence of 
heart disease dates back at least as far as the 1960s, when beneficial effects of 
calcium loading on circulating cholesterol levels were suggested [1].  The proposed 
mechanisms for this effect are binding of lipids and bile acids by calcium in the gut 
interfering with fat absorption [2-4], and possible indirect effects of vitamin D 
metabolites on lipid metabolism [5].  The calcium–cholesterol connection has been 
examined more rigorously since that time, with mixed results from randomized trials 
[3, 6-8].  There has been more extensive investigation of the effects of calcium 
supplements on blood pressure with a fairly consistent demonstration of average 
decrements of 1 – 2 mmHg in both systolic and diastolic pressures [9-11] in those 
allocated to calcium, and these effects may be greater in subjects with low dietary 
calcium intakes [8].  These findings, together with the possible inverse association 
between calcium intake and body weight [12], led to the suggestion that calcium 
supplements might decrease the incidence of cardiovascular events.  Running 
counter to this, however, has been evidence from patients with renal failure, in whom 
cardiovascular disease is one of the principal drivers of morbidity and mortality.  
While the presence of hyperphosphatemia in renal failure renders this a somewhat 
different situation from the normal, older postmenopausal women, there is 
accumulating evidence that the use of calcium salts as phosphate binders in both 
intermediate [13] and advanced [14] renal failure is associated with accelerated 
arterial calcification and increased mortality,. This has led to reduced use of non-
calcium phosphate binders in nephrology practice. 
 
Auckland Calcium Study 
In the light of the above evidence, we pre-specified several cardiovascular events as 
secondary endpoints in a prospective, randomized, placebo-controlled trial of calcium 
supplementation (1 g per day as the citrate) in 1471 normal, late postmenopausal 
women (mean age 74 years).  Contrary to our hypothesis of benefit, the subjects’ 
self-reports of adverse events showed a two-fold excess of myocardial infarctions 
(MI) and a 44% increase in the risk of stroke (non-significant) [15].  Because of this 
unexpected outcome and the potential importance of this issue, we collaborated with 
a cardiologist and a neurologist to formally adjudicate all of these events, and used a 
national register of hospital admissions to maximize event capture.  The adjudication 
process resulted in some changes in the numbers of individual events but the 
increased risk in the calcium group remained, there being a 49% excess in numbers 
of women with myocardial infarction (P=0.16) and a 43% increase in the rate ratio of 
the pre-specified composite endpoint of  myocardial infarction, stroke or sudden 
death (P=0.04) [15]. 
 
These findings raised a major concern regarding the safety of calcium supplements 
but did not provide definitive evidence. The conventional response to potentially 
important findings of borderline statistical significance is to conduct a definitive trial. 
Such a study, powered to detect a 20% difference in cardiovascular events between 
calcium and placebo groups, would need >20,000 participants followed for >5 years. 
While this is theoretically feasible, the ethical and recruitment problems that arise 
from testing a hypothesis of harm make this effectively impossible. Therefore, the 
only practical way to further address this question was to access data on cardiac 
safety from existing trials, in the hope that an adequately powered meta-analysis 
might be possible. 
 
Meta-analysis of Calcium Supplements and Vascular Events 
We have recently published such an analysis of adverse event data from randomized 
controlled trials of calcium supplements [16]. Having drafted a protocol for this meta-
analysis, we contacted the principal investigators of the 15 eligible trials inviting their 
participation and comments on the protocol. Suggested amendments were 
incorporated into the protocol, which was reviewed and approved by all investigators 
participating in the patient-level meta-analysis before data collation commenced. The 
intent was to collect patient-level data on cardiovascular events that occurred during 
each of the studies. Where such data were not available, trial-level summary data 
were requested. Of 15 eligible trials, cardiovascular data were not available in 4, 
patient-level data were available from 5 (8,151 participants, median follow-up 3.6y) 
and trial-level data were available from 11 (11,921 participants, median follow-up 4y). 
In 10 of the 11 trials providing data for analysis, calcium supplements were studied at 
a dose of at least 1000 mg daily. The average age of participants was 73y, and 83% 
were women. Thus, the participants were similar demographically to the group within 
the general population which is most commonly prescribed calcium supplements. 
Cardiovascular disease was not a primary endpoint of any of the trials, and events 
were ascertained variously by participants’ self-reports, hospital admission data, and 
death certificates. The pre-specified primary endpoints of the analysis were time to 
first MI, time to first stroke, and time to first event for the composite endpoint of MI, 
stroke, or sudden death. 
 
The results of the meta-analysis of both individual patient-level and trial-level data 
are summarized in Figure 1. In both analyses, allocation to calcium supplements 
conferred a significant, approximately 30%, increase in the risk of MI, and smaller, 
non-significant increases in the risks of stroke, the composite of MI, stroke and 
sudden death, and total mortality. The individual-patient level analysis provides an 
insight into the timing of the adverse effect of calcium supplements, and suggests 
that the increase in risk of MI begins soon after commencing treatment. The results 
of the trial-level analysis, incorporating data from 11 trials, demonstrate a striking 
consistency of effect in those studies that reported a substantial number of events. 
Calcium supplementation also tended to increase the risk of recurrent events, so that 
the relative risks of total events were increased by 24-32%. 
 
Responses to Meta-Analysis 
As expected, the meta-analysis has caused much discussion, both in the lay and 
scientific media, and prompted the development of position statements from 
international bone and mineral societies. A number of important issues have been 
raised (http://www.bmj.com/content/341/bmj.c3691/reply#bmj_el_240991), each of 
which will now be discussed.  
 
A potential limitation of our meta-analysis is that cardiovascular outcomes were not 
the primary endpoints of any of the contributing studies (although they were pre-
specified secondary endpoints in two of the Auckland studies [15, 17]), and 
consequently data on these outcomes were not gathered in a standardized manner. 
The events were obtained variously from self-reports, hospital admissions, death 
certificates, or adjudication of medical records. The RECORD study was the single 
largest contributor of participants, and diagnoses were based on self-reports of 
Cardiovascular events were not primary study endpoints 
hospital admissions, and data from death certificates. The latter were the source for 
about 60% of MI, and 46% of strokes in that study. Two key facts address these 
concerns. First, the magnitude of the increased risk of MI with calcium was consistent 
across the trials irrespective of the method of event ascertainment. Secondly, the 
likelihood of differential misclassification or misreporting of cardiovascular events by 
treatment allocation is small, because the data came from blinded, placebo-controlled 
trials. The use of variable methods for collecting adverse event reports will introduce 
noise, not bias, and would tend to obscure a true effect rather than introduce a false 
one. This contention is supported by the results of the adjudication process of self-
reported events from the Auckland Calcium Study, which changed the numbers of 
events in the two groups but not the asymmetry of their distribution [15]. It has also 
been suggested that failure of randomization may have produced an uneven 
distribution of risk factors for cardiovascular disease. This is unlikely across the 
number and size of studies included in the meta-analysis, and is not supported by 
examination of the baseline data from the calcium and placebo groups.  
 
Others have suggested that the effects might be related to trial- or participant-related 
characteristics, such as gender or type of calcium supplement used. However, there 
was no interaction between age, gender, baseline vitamin D status, or type of 
supplement used and risk of MI, stroke, or the composite endpoint with calcium 
(Figure 2). When the cohort was divided into 2 groups by baseline dietary calcium 
intake (above and below the median), there was an interaction between dietary 
calcium and the risk of MI (but not stroke or the composite endpoint) with calcium. 
But when the cohort was divided by quintile of baseline dietary calcium intake, there 
was no evidence of a dose-response relationship between baseline dietary calcium 
and the risk of MI with calcium, and in 4 of the 5 groups, the hazard ratios exceeded 
1 and were similar to the hazard ratio for the entire cohort (Figure 2). 
Adverse effect restricted to subgroups 
 
Some have questioned the internal consistency of the data since the increase in risk 
of MI is not accompanied by increased mortality. About 10-20% of individuals having 
an MI die as a result of that event, so the 30% increase in MI found with calcium use 
should result in a 3-6% increase in mortality.  In fact, there is a 9% increase in 
mortality with calcium in the patient-level analysis and a 7% increase in the trial-level 
analysis, consistent with expectations. These results were not statistically significant, 
but the study did not have the power to detect differences of this magnitude. 
Hormone therapy and rosiglitazone are other examples of interventions that increase 
risk of MI to a similar degree as calcium supplements without evidence for a 
significant increase in mortality [18, 19] 
No effect on mortality 
  
The exclusion of studies of co-administered calcium and vitamin D potentially limits 
the generalizability of the meta-analysis, since these agents are commonly taken 
together. However, the same could be said of the many other medications that are 
used in this age group and so will be co-administered with calcium, such as statins, 
aspirin and many more. This argument is only persuasive if a specific mechanism by 
which an agent might reverse the calcium effect can be identified, or if there are trial 
data suggesting an interaction. There is weak evidence that vitamin D might have an 
independent beneficial effect on mortality [20, 21] but unless this specifically prevents 
Effect of calcium and vitamin D 
the adverse effect of calcium, patients taking both agents could still be worse off than 
those taking vitamin D alone. One of the studies included in the meta-analysis did 
compare calcium and vitamin D with vitamin D alone [22], and found risks of MI and 
stroke comparable to those obtained from analysis of studies of calcium 
monotherapy.  
 
The Women’s Health Initiative (WHI) analyzed the effects of calcium with vitamin D 
on vascular outcomes in 36,000 women followed for seven years [23]. The hazard 
ratio for MI or coronary heart disease death in the whole cohort was 1.04 (95%CI, 
0.92–1.18), but for those without risk factors for coronary heart disease it was 1.19 
(95%CI, 0.97-1.59).  For the composite endpoint of MI, coronary heart disease death, 
coronary artery bypass graft or percutaneous coronary intervention, the hazard ratio 
in the entire cohort suggested an adverse effect (1.08, 95%CI, 0.99-1.19). Vascular 
risk associated with randomization to calcium/vitamin D was related to body mass 
index (BMI) (P=0.04) such that women with higher BMI were at lower risk from 
calcium/vitamin D supplementation [23]. For participants with BMI of 25-30, the 
hazard ratio for coronary heart disease was 1.18, and for BMI <25 it was 1.16. The 
overall conclusion of the WHI investigators was that intervention with calcium plus 
vitamin D did not change the risk of cardiovascular events. 
 
The participants in the WHI differed in a number of respects from those in our recent 
meta-analysis. They were ~10 years younger, heavier, 50% were taking hormone 
replacement therapy, and they had higher calcium intakes as a result of widespread 
use of non-trial calcium supplements. Over half of the WHI participants were taking 
calcium supplements at trial entry. We have now re-analyzed this study to determine 
whether non-protocol use of calcium supplements might have influenced the 
outcome. There are significant interactions between the effects of randomization to 
calcium-vitamin D on MI, stroke, and the combination of stroke or MI, and self-
administration of calcium (0.006<P<0.045). In those not using non-protocol calcium 
supplements, there was a ~20% increase in frequency of these events (P=0.05) [24]. 
While this is not conclusive in its own right, it does suggest that the original analysis 
of cardiovascular events in WHI was misleading because it did not recognize the 
interaction with use of non-protocol calcium supplements. Once this is allowed for, 
the results appear to be comparable to those of the meta-analysis of trials of calcium 
monotherapy. Cardiovascular event data comparing subjects treated with calcium-
vitamin D and placebo are also available for the RECORD and Lappe [25] studies. 
When these are meta-analyzed with the WHI data for patients not self-medicating 
with calcium, essentially the same results as in the WHI reanalysis are found.  
 
Some correspondents have pointed out that the mean total intake from dietary 
calcium and calcium supplements in the trials in our meta-analysis (~1800 mg/day) 
exceeds the recommended intake for postmenopausal women. It is important to note 
that clinical trials and observational data both suggest that the skeletal effects of 
calcium supplementation alone are small [26], and evidence of benefit has only been 
demonstrated in trials evaluating doses of calcium similar to those in the meta-
analysis. In a recent meta-analysis of the effect of calcium supplements with or 
without vitamin D on fractures [27], 15 of the 16 studies with fracture as an endpoint 
administered at least 750 mg/day of calcium supplement, and in 10 of the 13 studies 
that reported baseline dietary calcium intake, the total calcium intake (diet + 
Lower doses of calcium supplements might be adequate 
supplements) was at least 1500 mg/day (range 1230-2300mg/day). There is no 
robust evidence that calcium supplements in doses <1000 mg/day or total calcium 
intake <1500 mg/day prevent fractures, and we have recently failed to detect any 
effect of a supplement of 600 mg/day on bone density in normal men [17]. Thus, the 
beneficial skeletal effects of calcium have only been demonstrated in trials evaluating 
the same doses of calcium that also increase risk of MI. 
  
Wang et al recently published a meta-analysis of calcium effects on cardiovascular 
events, which appeared to be reassuring [28]. They reported a relative risk of 1.14 
(95% confidence interval 0.92-1.41) for cardiovascular events based on 3 
randomized trials of calcium supplements. We found risks of similar magnitude for 
the composite of MI, stroke, or sudden death in our patient-level analysis (hazard 
ratio 1.18) and trial-level analysis (relative risk 1.12). The consistency of results is not 
surprising because all of the trials included in the Wang meta-analysis were also 
included in our meta-analysis. However, our meta-analysis included more trials, 
captured more events, and therefore had greater statistical power than that of Wang. 
We also reported data for MI and stroke separately. 
Apparent conflict with other recent studies 
 
Data for self-reported events provided by the investigators of a Perth study [29] were 
included in our meta-analysis, but these investigators have recently published 
analyses of hospital admission data from that study [30]. They do not provide data for 
MI in this paper, but use a novel composite endpoint of atherosclerotic vascular 
mortality or first-hospitalisation, which includes diagnoses as diverse as arrhythmias 
and heart failure. The choice of such a diverse composite endpoint runs contrary to 
current recommendations [31]. The adjusted hazard ratio for this endpoint was 0.94 
(95% CI 0.69-1.28). Despite the width of these confidence intervals and the low 
power of a single study of this size, they conclude that this analysis provides 
“compelling evidence” that calcium supplementation does not significantly increase 
the risk of vascular disease, whereas this confidence interval includes the hazard 
ratio found in the meta-analysis, albeit for a somewhat different endpoint. Further 
data presented in abstract form from this study indicate that calcium supplements 
may also increase the risk of admission to hospital with abdominal problems, which is 
a further cause for concern [32].  
 
It is frequently stated that approved therapies for osteoporosis are only effective 
when co-administered with calcium and vitamin D.  This possibility has seldom been 
directly assessed, since this would require a randomized trial comparing the therapy 
plus calcium supplements, with the therapy administered alone.  There is a 
randomized controlled trial of alendronate that directly addresses this question, and 
showed no difference in changes in bone density over two years from the addition of 
calcium supplementation to alendronate (Figure 3) [33].  It is also possible to 
compare changes in bone density between trials of zoledronate with or without 
calcium. The one-year change in spine bone density in a study not using calcium co-
administration [34] was 4.8%, in comparison with a change of 4.0% in the phase 3 
trial which co-administered calcium and vitamin D [35].  It is also sometimes stated 
that anti-fracture efficacy for osteoporosis treatments has not been demonstrated 
without co-administration of calcium and vitamin D.  The McCloskey trial of 
clodronate [36] did not use either calcium or vitamin D and showed a comparable 
Osteoporosis treatments only work with calcium co-administration 
decrease in non-vertebral fracture to that found with much more potent 
antiresorptives, such as zoledronate  [35] and denosumab [37], though hip fractures 
were not reduced in this unselected cohort.  Also, anti-fracture efficacy of estrogen 
has been demonstrated without co-administration of calcium or vitamin D [38].  While 
it would be desirable to have more extensive documentation of the effects of all of the 
therapeutic interventions used in the absence of calcium supplementation, the 
balance of current evidence suggests that calcium supplements do not substantially 
impact on the efficacy of these medications.  
Mechanisms of Calcium Supplement Effect on Vascular Disease 
The pathogenic mechanisms by which the use of calcium supplements increases the 
risk of cardiovascular events are open to speculation.  It is noteworthy that there is no 
evidence of a positive relationship between dietary calcium intake and cardiovascular 
disease [39-41], though this is based on observational studies whose findings are 
often at odds with those from randomized trials, and few individuals in these studies 
had total calcium intakes >1800 mg/day, the median intake in the randomized trials in 
our meta-analysis. With these caveats, the absence of a signal from dietary calcium 
suggests that it is the use of a non-food supplement that increases cardiovascular 
risk, rather than simply the total calcium intake.  Numerous studies have shown acute 
increases in serum calcium into the borderline hypercalcemic range, following 
ingestion of 500–1000 mg of calcium as a supplement [42-45] (Figure 4).  This is in 
marked contrast to the ingestion of calcium-rich foods, which produce much smaller 
excursions in serum calcium [46], presumably because their transit through the upper 
gastrointestinal tract is much slower as a result of their significant contents of protein 
and fat.  Thus, it is tempting to relate the cardiovascular effects of calcium 
supplements to the transient hypercalcemia that follows their administration. 
 
There is an important related literature which considers the impact of high-normal 
levels of serum calcium on cardiovascular disease.  Rubin [47] has shown that mean 
carotid artery plaque thickness is 50% greater in normal older Americans whose 
serum calcium is in the top quintile, when compared with those in the bottom quintile.  
Similarly, we have shown that for each 0.1 mmol/L increase in serum calcium, the 
likelihood of abdominal aortic calcification increases by 23%, in a population of 
normal older women [48].  These changes in the arterial wall are paralleled by 
increases in cardiovascular events. Slinin [49] has shown that the combined 
incidence of stroke and coronary heart disease increases by 17% for each standard 
deviation increase in serum calcium in osteoporotic postmenopausal women. Lind 
demonstrated a 2.5-fold increase in the risk of MI across the measured range of 
calcium concentrations in 2000 50-year old men followed for 18 years [50]. Foley has 
shown risk of stroke, but not coronary heart disease, to be related to serum calcium 
in a cohort of nearly 16,000 men and women, mean age 54 years, followed for 13 
years [51].  In a retrospective study of 13,000 men, serum calcium was a predictor of 
myocardial infarction after adjustment for other cardiovascular risk factors, with an 
odds ratio of 1.2 per 0.1 mmol/L increase in serum calcium (P<0.0001) [52]. In 
normal Swedish men aged under 50, Leifsson has shown a steep relationship 
between 10-year mortality (predominantly cardiovascular) and baseline serum 
calcium [53].  In this study, a serum calcium between 2.50 and 2.55 mmol/L 
conferred a 50% increase in mortality compared with a calcium between 2.30 and 
2.45 mmol/L. Similarly, primary hyperparathyroidism has been associated with 
increased risk of vascular events [54].   
 
Thus, a simple explanation of the calcium supplement effect would be that a 
supplement moves an individual into the upper range of serum calcium for up to six 
hours following each dosing, and thus increases their cardiovascular risk.  Indeed, 
the increase in ionized calcium of 0.08 mmol/L that has been observed after 
supplement ingestion [42, 43] would equate to an increase in cardiovascular event 
rates of 27%, based on the data in the Slinin study.  This is very similar to what was 
observed in the meta-analysis, which is surprising since the increase in serum 
calcium following calcium supplements lasts only about 6 hours, though many 
individuals take more than one supplement daily. Possibly it is peak rather than mean 
levels of calcium which drive the adverse cardiovascular effects. If the acute changes 
in serum calcium following supplement ingestion are critically important, then it would 
also be important to determine the effect of taking a calcium supplement with or 
immediately after a meal. This would be expected to blunt the excursion in serum 
calcium, so it could be hypothesized that this might also reduce the adverse 
cardiovascular effects of calcium supplements.  
If higher levels of serum calcium increase vascular risk, then the mechanisms of this 
still remain to be determined.  The documentation of increased carotid artery plaque 
thickness and abdominal aortic calcification suggest a vessel wall effect. Similarly, in 
patients with renal impairment, acceleration of coronary artery calcification 
associated with calcium supplement use has been clearly documented [13].  If this is 
what indeed occurs, then it is unlikely to be a simple physicochemical process, since 
vascular calcification is a regulated, cell-mediated phenomenon [55].  Pyrophosphate 
is an important inhibitor of tissue calcification which also complexes with calcium, so 
its levels would be expected to be reduced when extracellular fluid calcium 
concentrations rise.  We have measured two other regulators of vascular 
calcification, osteoprotegerin and matrix gla protein, in subjects taking calcium 
supplements, but failed to show any difference from controls  [56].  The effect of 
increased calcium concentrations could be directly on the cells of the vessel wall, 
mediated through the calcium sensing receptor.  This possibility is supported by the 
demonstration in vitro that matrix vesicle formation and calcium incorporation into 
cultures of vascular smooth muscle cells are both increased at higher media calcium 
concentrations [57] and the fact that polymorphisms of the calcium sensing receptor 
are associated with cardiovascular mortality [58]. Increased circulating calcium 
concentrations will also reduce parathyroid hormone (PTH) levels, and PTH has 
been shown to inhibit arteriosclerotic Wnt/β-catenin signaling in vascular smooth 
muscle cells [59].  
 
The time-course of the cardiovascular events in the meta-analysis may provide some 
insights into pathogenesis.  Much of the increase in risk of myocardial infarction 
occurs within the first year, though there is a continued divergence of the two groups 
on the Kaplan-Meier plot subsequently.  In contrast, the divergence of stroke 
incidence between the two groups only begins at about one year and progressively 
increases subsequently.  This difference in time-course could reflect the different size 
of arteries involved in myocardial infarction and stroke, or it could indicate that a 
mechanism other than progressive vascular calcification is contributing to the early 
increase in myocardial infarction.  One such possibility would be the induction of a 
hypercoagulable state associated with increased serum calcium.  Since calcium is 
integral to many stages of the coagulation process and to platelet function, such a 
possibility is plausible.  Indeed, it has been demonstrated that the acute induction of 
severe hypercalcemia in rats is associated with a 50% reduction in clotting time [60].  
That this might also occur with more physiological perturbations of circulating calcium 
is suggested by an in vitro study of human blood in which the time to the initiation of 
coagulation is found to be inversely related to ionized calcium concentration, over a 
range from 0.6 to 1.7 mmol/L (Figure 5) [61].  
 
A third mechanism by which increases in serum calcium could have an early effect 
on cardiovascular morbidity is by way of its effects on arterial stiffness. This has been 
assessed in several contexts. Studies in patients with mild primary 
hyperparathyroidism have shown impaired indices of vasodilatation [62, 63]. In 
patients undergoing hemodialysis, the induction of mild hypercalcemia, through use 
of a high-calcium dialysate, results in acute increases in arterial stiffness assessed 
by digital photoplethysmography [64]. Supportive data comes from studies of normal 
volunteers in whom increases in serum ionized calcium of 0.3 mmol/L increase 
systolic blood pressure (mean±SD, 114±13 to 121±10 mmHg; P < 0.05) and result in 
dose-related impairment in endothelial vasodilator function [65]. 
 
Conclusions 
Our recent meta-analysis raises the possibility that calcium supplements increase 
cardiovascular risk. This finding is consistent with clinical trials of calcium 
supplements in patients with renal impairment, and with epidemiological data relating 
circulating calcium concentrations to cardiovascular disease in normal populations. 
There are a number of plausible pathophysiological mechanisms for these effects.  
 
A key question that then arises is whether the size of this adverse effect is large 
enough to negate the benefit of calcium use for skeletal health - the likelihood that 
calcium increases vascular events needs to be balanced against its only modest 
effects on fracture rates. When the change in number of events is calculated from the 
meta-analysis data, we find that treatment of 1000 women with calcium for 5 years 
results in 14 more MIs, 10 more strokes and 13 more deaths, while reducing the 
number of fractures by 26 [16]. These analyses need to be repeated using 
populations of different ages with different risk profiles, to determine how 
generalizable these findings are. However, we have carried out a similar analysis in 
the low-risk population of the WHI, and have also found that the increased 
cardiovascular risk negates the small benefit from fracture prevention. How the risk-
benefit is influenced by differences in the dose of calcium and vitamin D also needs 
further study. Based on the best evidence available, it seems likely that there is no 
net benefit from use of calcium supplements, and there may well be net detriment. 
Since food sources of calcium produce similar benefits on bone density as 
supplements [66, 67] (although effects on fracture are unclear), and have not been 
associated with adverse cardiovascular effects, these may be a better option as the 
principal calcium source. This suggestion is supported by the fact that calcium-rich 
meals have little effect on serum calcium concentrations. A move away from 
supplements may make lower target calcium intakes necessary, since >1000 mg/day 
may be difficult for many patients to achieve. Optimization of vitamin D status [68] to 
facilitate absorption of dietary calcium remains a sensible measure for the 
maintenance of bone health. 
 
The borderline anti-fracture efficacy of calcium means that it should not be relied on 
as the primary therapy in anyone with a substantially increased fracture risk – such 
patients require therapies proven to prevent fractures. Available evidence suggests 
that these therapies will be effective without co-administration of calcium 
supplements.  
 
Legends to Figures 
Effect of calcium supplements on risk of myocardial infarction from an individual 
patient meta-analysis of 5 trials (8151 participants), and a trial level analysis of 11 
studies (11921 subjects). Significant increases in risk were shown for both analyses. 
Figure from Bolland et al [16], used with permission. 
Figure 1 
 
Effect of calcium supplementation on myocardial infarction (MI) in participant 
subgroups. Data are from the meta-analysis of Bolland et al [16], and are drawn from 
the 5 studies that contributed patient-level data.  
Figure 2 
 
Changes in bone mineral density in the lumbar spine (A) and femoral neck (B) in 
postmenopausal women with low bone density randomized to treatment with 
alendronate, alendronate plus calcium, or calcium alone, over 2 years. Asterisks 
denote differences between the alendronate and calcium groups, and daggers 
differences between the alendronate+calcium and calcium groups, respectively. 
There were n differences between the alendronate alone and alendronate+calcium 
groups. From Bonnick et al ) [33], used with permission.  
Figure 3 
 
Changes in serum ionized calcium concentration following administration of control 
(squares), calcium citrate (triangles), calcium carbonate (asterisks), or potassium 
citrate (circles). The calcium doses were both 1g. † denotes a significant difference 
from control, and ‡ denotes difference from potassium citrate. From Karp et al [43], 
used with permission. 
Figure 4 
 
Relationship between the time to the initiation of coagulation (r-time) and ionized 
calcium concentrations in in vitro studies of human blood samples. For ionized 
calcium values above 0.56 mmol/L, the correlation with r-time was -0.48 (P<0.001). 
From James et al [61], used with permission. 
Figure 5 
 
Possible sequence of events that might contribute to the acceleration of vascular 
disease by calcium supplementation. As discussed in the text, there is evidence for 
each component shown in this pathway, mostly from observational studies in normal 
cohorts stratified by baseline serum calcium level, but there may be other pathways 
and other intermediate steps that are not yet known. Meta-analysis of trial data show 
an increase in cardiovascular events, but not in mortality, though increased mortality 
has been shown to be associated with high-normal serum calcium concentrations in 
a prospective observational study. Copyright IR Reid, used with permission. 
Figure 6 
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